Susquehanna Fundamental Investments LLC Invests $6.46 Million in Inari Medical, Inc. (NASDAQ:NARI)

Susquehanna Fundamental Investments LLC acquired a new stake in Inari Medical, Inc. (NASDAQ:NARI) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 134,205 shares of the company’s stock, valued at approximately $6,462,000. Susquehanna Fundamental Investments LLC owned about 0.23% of Inari Medical at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of NARI. BI Asset Management Fondsmaeglerselskab A S bought a new position in Inari Medical during the first quarter valued at about $30,000. GAMMA Investing LLC increased its holdings in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares in the last quarter. Covestor Ltd lifted its holdings in Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after purchasing an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Trading Up 1.3 %

Shares of NARI stock opened at $41.20 on Friday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $69.40. The company has a market capitalization of $2.40 billion, a P/E ratio of -100.49 and a beta of 1.00. The stock has a 50 day moving average of $46.60 and a two-hundred day moving average of $46.08.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. Sell-side analysts predict that Inari Medical, Inc. will post -0.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $50.08, for a total value of $150,240.00. Following the sale, the chief executive officer now owns 462,474 shares of the company’s stock, valued at approximately $23,160,697.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director William Hoffman sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00. Following the completion of the sale, the director now owns 805,359 shares of the company’s stock, valued at $40,388,753.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $50.08, for a total value of $150,240.00. Following the completion of the transaction, the chief executive officer now directly owns 462,474 shares in the company, valued at $23,160,697.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 155,520 shares of company stock valued at $8,111,707. 10.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on NARI shares. Wells Fargo & Company dropped their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 price target for the company. Stifel Nicolaus assumed coverage on Inari Medical in a research report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target on the stock. Piper Sandler restated a “neutral” rating and set a $50.00 target price on shares of Inari Medical in a research note on Monday, August 26th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $55.00 target price (down previously from $60.00) on shares of Inari Medical in a report on Wednesday, July 31st. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $58.44.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.